Log in

NASDAQ:KLDO - Kaleido Biosciences Stock Price, Forecast & News

-0.25 (-3.61 %)
(As of 02/18/2020 04:41 AM ET)
Today's Range
Now: $6.68
50-Day Range
MA: $6.82
52-Week Range
Now: $6.68
Volume113,143 shs
Average Volume228,039 shs
Market Capitalization$200.80 million
P/E RatioN/A
Dividend YieldN/A
Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:KLDO



Sales & Book Value

Annual SalesN/A



Market Cap$200.80 million
Next Earnings Date2/19/2020 (Estimated)
OptionableNot Optionable

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences Inc (NASDAQ:KLDO) announced its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.15. View Kaleido Biosciences' Earnings History.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Kaleido Biosciences.

What price target have analysts set for KLDO?

5 brokers have issued 1 year price objectives for Kaleido Biosciences' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Kaleido Biosciences' stock price to reach $17.70 in the next year. This suggests a possible upside of 165.0% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.

What is the consensus analysts' recommendation for Kaleido Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.

Has Kaleido Biosciences been receiving favorable news coverage?

Media coverage about KLDO stock has trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kaleido Biosciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Kaleido Biosciences.

Are investors shorting Kaleido Biosciences?

Kaleido Biosciences saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,820,000 shares, an increase of 20.5% from the December 31st total of 1,510,000 shares. Based on an average daily volume of 126,200 shares, the short-interest ratio is currently 14.4 days. Approximately 20.2% of the company's stock are sold short. View Kaleido Biosciences' Current Options Chain.

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Precision BioSciences (DTIL), Gossamer Bio (GOSS), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Exxon Mobil (XOM), QUALCOMM (QCOM), Pfizer (PFE) and Akero Therapeutics (AKRO).

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the folowing people:
  • Mr. Michael W. Bonney, Exec. Chair (Age 61)
  • Ms. Alison Lawton, CEO, Pres & Director (Age 58)
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder & Director (Age 56)
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 38)
  • Mr. Joshua T. Brumm, COO & CFO (Age 41)

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (6.94%), Victory Capital Management Inc. (0.43%), Victory Capital Management Inc. (0.43%), State Street Corp (0.40%), Goldman Sachs Group Inc. (0.37%) and Bank of America Corp DE (0.20%). Company insiders that own Kaleido Biosciences stock include Michael W Bonney and Ventures Fund V LP Flagship. View Institutional Ownership Trends for Kaleido Biosciences.

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors, Victory Capital Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Kaleido Biosciences.

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Jacobs Levy Equity Management Inc., State Street Corp, Oxford Asset Management LLP, Bank of New York Mellon Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Michael W Bonney and Ventures Fund V LP Flagship. View Insider Buying and Selling for Kaleido Biosciences.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $6.68.

How big of a company is Kaleido Biosciences?

Kaleido Biosciences has a market capitalization of $200.80 million. Kaleido Biosciences employs 118 workers across the globe.View Additional Information About Kaleido Biosciences.

MarketBeat Community Rating for Kaleido Biosciences (NASDAQ KLDO)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  79
MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote "Outperform" if you believe KLDO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Stock Portfolio Tracker

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel